Endocyte (NASDAQ: ECYT) and Dipexium Pharmaceuticals (NASDAQ:PLXP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Earnings and Valuation

This table compares Endocyte and Dipexium Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Endocyte $70,000.00 2,640.02 -$40.60 million ($1.02) -4.25
Dipexium Pharmaceuticals $375,950.00 173.32 -$8.09 million N/A N/A

Dipexium Pharmaceuticals has higher revenue and earnings than Endocyte.

Profitability

This table compares Endocyte and Dipexium Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Endocyte -61,437.14% -32.68% -31.29%
Dipexium Pharmaceuticals N/A -122.35% -91.84%

Volatility & Risk

Endocyte has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Dipexium Pharmaceuticals has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500.

Institutional and Insider Ownership

28.8% of Endocyte shares are owned by institutional investors. Comparatively, 19.7% of Dipexium Pharmaceuticals shares are owned by institutional investors. 14.9% of Endocyte shares are owned by company insiders. Comparatively, 47.7% of Dipexium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Endocyte and Dipexium Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Endocyte 0 1 2 0 2.67
Dipexium Pharmaceuticals 0 1 1 0 2.50

Endocyte currently has a consensus price target of $7.00, suggesting a potential upside of 61.29%. Given Endocyte’s stronger consensus rating and higher possible upside, research analysts plainly believe Endocyte is more favorable than Dipexium Pharmaceuticals.

Summary

Endocyte beats Dipexium Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

About Endocyte

Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), the Company’s second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company’s non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

About Dipexium Pharmaceuticals

PLx Pharma Inc., formerly Dipexium Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen. PLxGuard delivery system uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs to selectively release these drugs to targeted portions of the GI tract. The Company’s lead product Aspertec 325 mg is a liquid-fill aspirin capsule for prevention of cardiovascular disease. Through PLxGuard delivery system the Company creates a lipid-based formulation of ibuprofen, PL1200 Ibuprofen Capsules, 200 mg.

Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.